PathFinder™ Granted Market Authorization by NMPA

Shanghai, China - On June 20, MicroPort NeuroTech (Shanghai) Co., Ltd., a subsidiary of MicroPort NeuroTech Limited (02172.HK, hereinafter referred to as “MicroPort NeuroTech”, announces that its developed PathFinder™ carotid balloon dilation catheter (“PathFinder™”) has been granted market authorization by National Medical Products Administration (NMPA). PathFinder™ is primarily used for percutaneous transluminal angioplasty in patients with carotid artery occlusive disease, which is effective in dilating and unclogging narrowed blood vessels during treatment. The successful marketing of PathFinder™ will further enrich the product portfolio of MicroPort NeuroTech intended for treatment of cerebral atherosclerotic stenosis, further providing more therapeutic options to patients with cerebrovascular diseases. Up to now, MicroPort NeuroTech already has 20 neurointerventional therapy and neurointerventional pathway products approved for commercialization, covering all key areas of neurovascular disease.